MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 317322 | Name: Bevantolol Hydrochloride
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bevantolol Hydrochloride is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension.

Chemical Structure

Bevantolol Hydrochloride
Bevantolol Hydrochloride
CAS#42864-78-8 (HCl)

Theoretical Analysis

MedKoo Cat#: 317322

Name: Bevantolol Hydrochloride

CAS#: 42864-78-8 (HCl)

Chemical Formula: C20H28ClNO4

Exact Mass: 0.0000

Molecular Weight: 381.89

Elemental Analysis: C, 62.90; H, 7.39; Cl, 9.28; N, 3.67; O, 16.76

Price and Availability

Size Price Availability Quantity
100mg USD 350.00 2 Weeks
250mg USD 650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
59170-23-9 (free base) 42864-78-8 (HCl)
Synonym
Bevantolol Hydrochloride; Bevantolol HCl; Vantol; Cl 775; Cl775; Cl 775; DL-Bevantolol; NC-1400; NC1400; NC 1400
IUPAC/Chemical Name
1-[2-(3,4-dimethoxyphenyl)ethylamino]-3-(3-methylphenoxy)propan-2-ol, hydrochloride
InChi Key
FJTKCFSPYUMXJB-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H27NO4.ClH/c1-15-5-4-6-18(11-15)25-14-17(22)13-21-10-9-16-7-8-19(23-2)20(12-16)24-3;/h4-8,11-12,17,21-22H,9-10,13-14H2,1-3H3;1H
SMILES Code
OC(COC1=CC=CC(C)=C1)CNCCC2=CC=C(OC)C(OC)=C2.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 381.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kaplan HR. Bevantolol hydrochloride--preclinical pharmacologic profile. Angiology. 1986 Mar;37(3 Pt 2):254-62. doi: 10.1177/000331978603700319. PMID: 2871786. 2: Löfdahl CG, Svedmyr K, Svedmyr N. Selectivity of bevantolol hydrochloride, a beta 1-adrenoceptor antagonist, in asthmatic patients. Pharmacotherapy. 1984 Jul-Aug;4(4):205-10. doi: 10.1002/j.1875-9114.1984.tb03359.x. PMID: 6148733. 3: Takita M, Kigoshi S, Muramatsu I. Selectivity of bevantolol hydrochloride towards alpha- and beta-adrenoceptor subtypes in rat cerebral cortex. Jpn J Pharmacol. 1992 Feb;58(2):193-6. doi: 10.1254/jjp.58.193. PMID: 1354761. 4: Frishman WH, Goldberg RJ, Benfield P. Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. Drugs. 1988 Jan;35(1):1-21. doi: 10.2165/00003495-198835010-00001. PMID: 2894292. 5: Vaughan Williams EM. Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions. J Clin Pharmacol. 1987 Jul;27(7):450-60. doi: 10.1002/j.1552-4604.1987.tb03049.x. PMID: 2888789. 6: Kaplan HR. Pharmacology of bevantolol hydrochloride. Am J Cardiol. 1986 Nov 26;58(12):3E-7E. doi: 10.1016/0002-9149(86)90590-4. PMID: 2878599. 7: Ren L, Wang Z, Lou Y, Zheng L, Zheng H, Yin C. Determination of bevantolol in human plasma using liquid chromatography-electrospray ionization tandem mass spectrometry and its application to a bioequivalence study. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 May 15;959:16-21. doi: 10.1016/j.jchromb.2014.03.040. Epub 2014 Apr 13. PMID: 24747519. 8: Oh JW, Trung TQ, Sin KS, Kang JS, Kim KH. Determination of bevantolol enantiomers in human plasma by coupled achiral-chiral high performance-liquid chromatography. Chirality. 2007 Jul;19(7):528-35. doi: 10.1002/chir.20410. PMID: 17457831. 9: Bowles MJ, Khurmi NS, O'Hara MJ, Raftery EB. Usefulness of bevantolol for chronic, stable angina pectoris. Am J Cardiol. 1986 Nov 26;58(12):28E-34E. doi: 10.1016/0002-9149(86)90595-3. PMID: 2878598. 10: Farnham DJ. Effectiveness of bevantolol in the treatment of angina--a placebo-controlled study. Angiology. 1986 Mar;37(3 Pt 2):226-32. doi: 10.1177/000331978603700314. PMID: 2871782. 11: Latts JR. Clinical pharmacokinetics and metabolism of bevantolol. Angiology. 1986 Mar;37(3 Pt 2):221-5. doi: 10.1177/000331978603700313. PMID: 2871781. 12: Dukes ID, Vaughan Williams EM. Cardiovascular effects of bevantolol, a selective beta 1-adrenoceptor antagonist with a novel pharmacological profile. Br J Pharmacol. 1985 Feb;84(2):365-80. doi: 10.1111/j.1476-5381.1985.tb12921.x. PMID: 2858236; PMCID: PMC1987306. 13: Gamez J, Calopa M, Muñoz E, Ferré A, Huertas O, McAllister K, Reig N, Scart- Grès C, Insa R, Kulisevsky J. A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease. Br J Clin Pharmacol. 2023 May;89(5):1656-1664. doi: 10.1111/bcp.15635. Epub 2022 Dec 28. PMID: 36494329. 14: Fairhurst GJ. Comparison of bevantolol and atenolol for systemic hypertension. Am J Cardiol. 1986 Nov 26;58(12):25E-27E. doi: 10.1016/0002-9149(86)90594-1. PMID: 2878597. 15: Bray JS. Safety profile of bevantolol. Angiology. 1986 Mar;37(3 Pt 2):248-53. doi: 10.1177/000331978603700318. PMID: 2871785. 16: Maclean D. Bevantolol vs propranolol: a double-blind controlled trial in essential hypertension. Angiology. 1988 Jun;39(6):487-96. doi: 10.1177/000331978803900601. PMID: 2897812. 17: Noshiro T, Miura Y, Yoshinaga K, Iimura O, Inagaki Y, Saruta T, Ishii M, Yamazaki N, Arakawa K. Clinical evaluation of bevantolol hydrochloride in patients with severe hypertension. The Cooperative Study Group on Bevantolol in Japan. Int J Clin Pharmacol Ther. 1995 Apr;33(4):240-5. PMID: 7620695. 18: Shiraishi K, Moriya M, Miyake N, Takayanagi I. Alpha 1-adrenoceptor blocking activities of bevantolol hydrochloride(NC-1400) and labetalol in rat isolated thoracic aorta--do they distinguish between subtypes? Gen Pharmacol. 1992 Sep;23(5):843-5. doi: 10.1016/0306-3623(92)90235-c. PMID: 1358746. 19: Long PH, Trung TQ, Oh JW, Kim KH. Chiral purity test of bevantolol by capillaryelectrophoresis and high performance liquid chromatography. Arch Pharm Res. 2006 Sep;29(9):808-13. doi: 10.1007/BF02974083. PMID: 17024856. 20: Wong GW, Boyda HN, Wright JM. Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension. Cochrane Database Syst Rev. 2016 Mar 10;3(3):CD007451. doi: 10.1002/14651858.CD007451.pub2. PMID: 26961574; PMCID: PMC6486283.